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Background: Matrix gla protein (MGP) is a calcification-inhibitor and MGP-deficient mice develop extensive vascular calcification resulting in 
severe hemodynamic changes and early death from congestive heart failure (HF). Moreover, MGP could contribute to myocardial remodelling through 
“calcification-independent” mechanisms such as their effects on matrix remodelling. We hypothesized that patients with chronic HF would have 
dysregulated circulating MGP levels. 
Methods: We investigated circulating (by enzyme immunoassay) uncarboxylated MGP (dp-ucMGP) in patients with HF and investigated 
associations with clinical and biochemical measures of HF as well as associations with mortality/HTx. 
Results: Plasma dp-ucMGP was markedly increased in patients (n=181) compared to healthy controls (n=92) with increasing levels according 
to etiology (increased in ischemic disease, p=0.004) and functional (NYHA, p=0.001), hemodynamic (correlation LVEF, r=-0.25, p=0.002; WMSI, 
r=0.28, p=0.001), and neurohormonal disease severity (correlation NTproBNP, r=0.40, p<0.001). Further, when investigating associations with 
mortality, non-survivors or patients who underwent HTx during a follow-up of 3.1±1.5 (mean±SD) years, had increased plasma levels compared to 
survivors (p=0.043). Survival analysis revealed a significantly higher mortality/HTx rate in the highest quartile of dp-ucMGP [HR 1.85 (1.01-3.38), 
p=0.045]. The activation of MGP is highly vitamin K dependent and adjusting for the use of vitamin K antagonists in multi-variable analyses, with dp-
ucMGP as a continuous variable, still revealed predictive information for risk estimation. However, no predictive information for the risk estimation 
of was observed beyond demographic, clinical and biochemical variables (LVEF, NYHA class, etiology, age, sex, previous infarction, serum creatinine, 
LDL cholestrol and NTproBNP). 
Conclusion: Our data suggest a potential role for dp-ucMGP in the development of left ventricular dysfunction that should be further investigated.
